SEC Form 4 · accession 0001628280-26-042739
AbCellera Biologics Inc. · ABCL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 1:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001703057
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share option (right to buy)F1 | $5.27 | Jun 11, 2026 | A | 111,701 | A | Jun 10, 2027 | Jun 11, 2036 | Common Shares | 111,701 | 1,011,544 | D |
Explanation of responses
- F1The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.